Sponsor
Tammy Baldwin
Senator · D-WI
Senator · D-WI
The bill prioritizes earlier patient and hospital access to additional approved treatments within rare diseases by narrowing exclusivity to specific indications, at the cost of reducing revenue protections for developers and potentially weakening incentives to invest in therapies for less-common indications.
Patients with rare diseases could get earlier access to alternative therapies because exclusivity is limited to specific approved uses, allowing other drugs for different indications within the same rare disease to enter the market sooner.
Hospitals and health systems may have more approved treatment options for patients as narrower, indication-specific exclusivity permits additional products addressing different indications within the same rare disease.
Manufacturers of orphan-designated drugs—including small biotech firms—may face reduced market exclusivity for some follow-on products, lowering expected revenues from broader exclusivity claims.
Narrower exclusivity could discourage investment in developing therapies for less-common or secondary indications within a rare disease, potentially slowing innovation and leaving some patient subpopulations without new treatments.
Based on analysis of 2 sections of legislative text.
Limits orphan-drug exclusivity so it protects only a drug's specific approved use or indication rather than the whole rare disease or condition.
Changes to federal orphan-drug exclusivity narrow protection so that exclusivity applies to a drug’s specific FDA- or FDA-licensed approved use or indication, rather than broadly to the entire named rare disease or condition. The amendment revises statutory language that governs when others may seek approval of the same drug for related uses and defines “approved use or indication.” The change applies to any drug designated under the rare disease designation statute regardless of when it was designated, approved, or licensed, and will affect decisions by the FDA, innovator drug developers, and companies seeking approvals for related or overlapping uses.
Official title: Set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions.
Introduced January 28, 2026 by Tammy Baldwin · Last progress January 28, 2026